Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szoke

Showing results (261-270 of 287) with videos related to

Pageof 29
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2007
Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958Jon E Hawkinson, Balazs G Szoke, Albert W Garofalo, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 17, 2020
Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohortG Fond, O Godin, F Schürhoff, et al.
European Archives of Psychiatry and Clinical Neuroscience|July 19, 2022
The impact of parent history of severe mental illness on schizophrenia outcomes: results from the real-world FACE-SZ cohortA Garosi, P L Sunhary de Verville, D Etchecopar-Etchart, et al.
Journal of Affective Disorders|July 16, 2020
Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohortG Fond, T Korchia, P L Sunhary de Verville, et al.
Schizophrenia Bulletin|October 31, 2021
Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year StudyJulien Dubreucq, Franck Gabayet, Ophélia Godin, et al.
The New England Journal of Medicine|June 10, 2026
Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac SurgeryBrett L Houston, Daniel I McIsaac, Rodney H Breau, et al.
Schizophrenia Bulletin Open|December 13, 2021
Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) StudyMarion Leboyer, Ophélia Godin, Emilie Terro, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2018
High-resolution μCT of a mouse embryo using a compact laser-driven X-ray betatron sourceJason M Cole, Daniel R Symes, Nelson C Lopes, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|January 21, 2022
Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophreniaThéo Korchia, Maud Tastevin, Pierre-Louis Sunhary de Verville, et al.
Pageof 29

Showing results (261-270 of 287) with videos related to

Sort By:
Pageof 29
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2007
Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958Jon E Hawkinson, Balazs G Szoke, Albert W Garofalo, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 17, 2020
Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohortG Fond, O Godin, F Schürhoff, et al.
European Archives of Psychiatry and Clinical Neuroscience|July 19, 2022
The impact of parent history of severe mental illness on schizophrenia outcomes: results from the real-world FACE-SZ cohortA Garosi, P L Sunhary de Verville, D Etchecopar-Etchart, et al.
Journal of Affective Disorders|July 16, 2020
Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohortG Fond, T Korchia, P L Sunhary de Verville, et al.
Schizophrenia Bulletin|October 31, 2021
Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year StudyJulien Dubreucq, Franck Gabayet, Ophélia Godin, et al.
The New England Journal of Medicine|June 10, 2026
Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac SurgeryBrett L Houston, Daniel I McIsaac, Rodney H Breau, et al.
Schizophrenia Bulletin Open|December 13, 2021
Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) StudyMarion Leboyer, Ophélia Godin, Emilie Terro, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2018
High-resolution μCT of a mouse embryo using a compact laser-driven X-ray betatron sourceJason M Cole, Daniel R Symes, Nelson C Lopes, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|January 21, 2022
Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophreniaThéo Korchia, Maud Tastevin, Pierre-Louis Sunhary de Verville, et al.
Pageof 29